SCHEMBL9674

SCHEMBL9674

CC(=O)Nc1ccc(Br)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.81
ALDH1A1 P00352 3/20 0.81
SMN1; SMN2 Q16637 4/20 0.67
HTT P42858 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
EPHX1 P07099 1/20 0.66
KMT2A Q03164 6/20 0.64
MEN1 O00255 5/20 0.64
TSHR P16473 2/20 0.64
TDP1 Q9NUW8 1/20 0.64
CA12 O43570 1/20 0.64
BRD4 O60885 1/20 0.64
NR1I2 O75469 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
MB P02144 1/20 0.64
CYP1A1 P04798 1/20 0.64
CA3 P07451 1/20 0.64
CYP3A4 P08684 1/20 0.64
RARG P13631 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9339755 0.94 SMN1; SMN2 (0.79) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL4555020 0.94 MAPT (0.72) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL9342637 0.88 MAPT (0.66) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL19227677 0.88 MAPT (0.71) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL10925259 0.88 MAPT (0.66) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL861674 0.87 SMN1; SMN2 (0.84) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL10924363 0.87 PKM (0.72) MAPTALDH1A1EPHX1KMT2ACA12
SCHEMBL10927228 0.85 MAPT (0.62) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
Aniline SCHEMBL10956685 0.85 MAPT (0.62) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1
Acetanilide SCHEMBL28762299 0.85 NAPRT (0.79) MAPTALDH1A1SMN1; SMN2HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079858-A Preparation method of 5-bromoindole-2-carboxylic acid ethyl ester or 5-bromoindole-2-carboxylic acid 2026-05-26 CN claimed
CN-118948844-A Application of triazole derivative LD-18 in preparation of anti-type 2 diabetes medicine taking PPARgamma and alpha-glucosidase as targets 邵阳学院 2024-11-15 CN claimed
CN-113801015-B Method for synthesizing aromatic carboxylic acid compound by using carbon dioxide 华南理工大学 2022-11-18 CN claimed
CN-113801015-A Method for synthesizing aromatic carboxylic acid compound by using carbon dioxide 华南理工大学 2021-12-17 CN claimed
CN-109082280-B Preparation method of liquid crystal material 宁夏中星显示材料有限公司 2020-07-28 CN claimed
US-20120063996-A1 NOVEL NIMESULIDE COMPOSITIONS ELAN PHARMA INTERNATIONAL LTD. 2012-03-15 US claimed
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 US claimed
US-20090312433-A1 TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT AMGEN INC. 2009-12-17 US claimed
EP-1617816-B1 NANOPARTICULATE MELOXICAN FORMULATIONS ELAN PHARMA INT LTD (IE) 2009-05-13 EP claimed
EP-1938803-A2 Formulations comprising nanoparticulate meloxican Elan Pharma International Limited (IE) 2008-07-02 EP claimed
WO-2004082719-A1 DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS PHARMACIA CORPORATION (US) 2004-09-30 WO claimed
US-20040156872-A1 Novel nimesulide compositions ELAN PHARMA INTERNATIONAL LTD. 2004-08-12 US claimed
US-20030235617-A1 Pharmaceutical dosage form for mucosal delivery MCNEIL-PPC, INC 2003-12-25 US claimed
US-20030180357-A1 Pharmaceutical tablet MCNEIL-PPC, INC 2003-09-25 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0470669-B1 Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines DOWELANCO (US) 1997-11-12 EP claimed
EP-0470669-A2 Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines DOWELANCO (US) 1992-02-12 EP claimed
US-4643964-A COMPOSED OF ELECTROCONDUCTIVE PARTICLES, MELTABLE COMPOUND AND HYDROPHILIC BINDER FUJI PHOTO FILM CO., LTD. (JP) 1987-02-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040156872-A1 Novel nimesulide compositions NIM1K, NIT2, NCL MAPT 244/4885ALDH1A1 3888/4885SMN1; SMN2 136/4885
US-20030180357-A1 Pharmaceutical tablet GYPA, SORD, SRI MAPT 953/4885ALDH1A1 1900/4885SMN1; SMN2 2397/4885
US-20120063996-A1 NOVEL NIMESULIDE COMPOSITIONS NIM1K, NIT2, NCL MAPT 244/4885ALDH1A1 3888/4885SMN1; SMN2 136/4885
US-20090312433-A1 TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT VRK1, VIPR1, AVPR1A MAPT 4532/4885ALDH1A1 983/4885SMN1; SMN2 3787/4885
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents NOS2, NOS1, NOS3 MAPT 4304/4885ALDH1A1 204/4885SMN1; SMN2 2638/4885
US-20030235617-A1 Pharmaceutical dosage form for mucosal delivery SI, UGGT1, GYPA MAPT 2192/4885ALDH1A1 1722/4885SMN1; SMN2 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.